文献速递肾移植

不同免疫抑制方案对肥胖肾移植受者临床结局的影响:倾向性评分匹配分析

Impact of different immunosuppressive protocols on clinical outcomes in obese kidney transplant recipients: a propensity score-matched analysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该研究基于美国器官共享网络数据库,按体重指数和免疫抑制方案分组分析肥胖肾移植受者的临床结局。结果显示,重度肥胖(BMI≥35 kg/m2)受者中mTORi-Tac组急性排斥率(6.4%)低于Tac-MMF组(11.2%);肥胖1级(30<BMI<35 kg/m2)使用mTORi-Tac与急性排斥风险相关(HR 1.79,95%CI 1.21-2.62,P=0.003)。Tac-MMF组超重和肥胖受者心血管事件生存受损,重度肥胖者感染死亡率增加。

要点

  • 重度肥胖(BMI≥35 kg/m2)受者中,mTORi-Tac组急性排斥率6.4%,低于Tac-MMF组11.2%。
  • 肥胖1级(30<BMI<35 kg/m2)使用mTORi-Tac与急性排斥风险相关(HR 1.79,95%CI 1.21-2.62,P=0.003)。
  • Tac-MMF组超重和肥胖受者心血管事件生存显著受损,重度肥胖者感染死亡率增加。

核心结论

  • 在肥胖肾移植受者中,mTORi与钙调神经磷酸酶抑制剂联用与较低的排斥率和稳定的长期肾功能相关,同时减少钙调神经磷酸酶抑制剂相关心血管副作用。
  • 上述结果对日益增多的肥胖移植受者具有重要意义,但需前瞻性评估。

研究设计与样本

  • 基于美国器官共享网络数据库的分析。
  • 肾移植受者按体重指数和免疫抑制方案分组:他克莫司/吗替麦考酚酯(Tac-MMF)、mTOR抑制剂/他克莫司(mTORi-Tac)、mTORi/环孢素(mTORi-Cyc)和mTORi-MMF。

主要发现

  • 重度肥胖(BMI≥35 kg/m2)受者中,mTORi-Tac组移植后第一年急性排斥率为6.4%,低于Tac-MMF组的11.2%。
  • 肥胖1级(30<BMI<35 kg/m2)使用mTORi-Tac与急性排斥风险相关(HR 1.79,95%CI 1.21-2.62,P=0.003)。
  • Tac-MMF组重度肥胖者急性排斥风险趋势相似(HR 1.29,95%CI 0.96-1.73,P=0.087)。
  • Tac-MMF组超重和肥胖受者心血管事件生存显著受损,重度肥胖者感染死亡率增加。

局限性

  • 原文结论指出需前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although obesity has become a significant problem in transplantation medicine, the impact of different immunosuppressive protocols on clinical outcomes in obese transplant recipients remains unclear. METHODS: We performed an analysis of the Scientific Registry of Transplant Recipients database. Kidney transplant recipients were categorized according to body mass index (BMI) categories and immunosuppressive protocols: (i) tacrolimus/mycophenolate mofetil (Tac-MMF), (ii) mTOR-inhibitor/Tac (mTORi-Tac), (iii) mTORi/cyclosporin (mTORi-Cyc) and (iv) mTORi-MMF. RESULTS: Graft recipients with advanced obesity (BMI ≥35 kg/m2) exhibited significantly lower rates of acute rejection during the first year after transplantation in the mTORi-Tac (6.4%) group compared with Tac-MMF (11.2%). Obesity class 1 (30 < BMI < 35 kg/m2) was associated with a significant risk of acute rejection for the mTORi-Tac group [obesity class 1 hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.21-2.62, P = .003]. A similar trend was observed in the Tac-MMF group for advanced obesity HR 1.29; 95% CI 0.96-1.73, P = .087). For the Tac-MMF group, recipients with both overweight and obesity had significantly impaired survival due to cardiovascular events and also increased mortality due to infection in advanced obesity. Combination of mTORi and calcineurin inhibitor was associated with lower rejection rates and stable long-term kidney function while reducing cardiovascular side effects linked to calcineurin inhibitors in obese kidney graft recipients. CONCLUSION: These results are critical for the growing number of obese graft recipients and warrant prospective evaluation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Serna-Higuita LM, Della Penna A, Guthoff M, et al. Impact of different immunosuppressive protocols on clinical outcomes in obese kidney transplant recipients: a propensity score-matched analysis. Nephrol Dial Transplant. 2023. PMID: 36662032. doi:10.1093/ndt/gfad014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。